{
    "2021-01-26": [
        [
            {
                "time": "2021-02-04",
                "original_text": "Novartis Slammed: Expects Covid To Impact Drug Sales Until Mid-2021",
                "features": {
                    "keywords": [
                        "Covid",
                        "Drug Sales",
                        "Impact",
                        "Mid-2021"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-02-05",
                "original_text": "The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market",
                "features": {
                    "keywords": [
                        "Novartis Misses",
                        "J&J Beats",
                        "Earnings",
                        "CureVac",
                        "Equity Market"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-02-08",
                "original_text": "Novartis Gives Cautious Outlook and Warns Covid-19 Impact Will Last Until Mid 2021. The Stock Is Falling.",
                "features": {
                    "keywords": [
                        "Cautious Outlook",
                        "Covid-19",
                        "Impact",
                        "Stock Is Falling"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-02-09",
                "original_text": "Swiss Miss: Novartis Stock Falls As Novartis Earnings, Sales Fall Short Of Views",
                "features": {
                    "keywords": [
                        "Stock Falls",
                        "Earnings",
                        "Sales",
                        "Fall Short Of Views"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-02-10",
                "original_text": "Novartis: Q4 Earnings Insights",
                "features": {
                    "keywords": [
                        "Q4 Earnings",
                        "Insights"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-02-11",
                "original_text": "Merck Just Scrapped Its Coronavirus Vaccines â€” Is Merck Stock A Buy?",
                "features": {
                    "keywords": [
                        "Merck",
                        "Scrapped",
                        "Coronavirus Vaccines"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-02-12",
                "original_text": "Novartis CEO renews commitment to Sandoz generics unit",
                "features": {
                    "keywords": [
                        "CEO",
                        "Sandoz",
                        "generics",
                        "commitment"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-02-15",
                "original_text": "Novartis CEO: Hopeful to Accelerate Growth in Second Half",
                "features": {
                    "keywords": [
                        "CEO",
                        "Accelerate Growth",
                        "Second Half"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-02-16",
                "original_text": "Novartis CEO says U.S. approval timeline for Leqvio 'out of our control'",
                "features": {
                    "keywords": [
                        "CEO",
                        "U.S.",
                        "approval",
                        "Leqvio",
                        "control"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-02-17",
                "original_text": "Novartis's regulatory delays add to pandemic sales hit",
                "features": {
                    "keywords": [
                        "regulatory delays",
                        "pandemic",
                        "sales hit"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-02-18",
                "original_text": "Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.",
                "features": {
                    "keywords": [
                        "sales growth",
                        "margin expansion",
                        "next wave of medicines"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}